Pfizer Makes Plans For Interchangeable Adalimumab Filing

Company Sees Double-Digit Growth In Biosimilars Business In Q3 FY21

 
• By Akriti Seth
  
2023
Pfizer aims to launch its Abrilada (adalimumab-afzb) biosimilar to Humira in 2023 • Source: Alamy

More from Biosimilars

More from Products